+49 2066 50687-70

the 21st century

DISQVER is the platform for digital pathogen diagnostics from Noscendo. In very little time, it can identify over 16,000 microbes in a patient sample – including more than 1,500 harmful pathogens. This opens up new opportunities for patients, doctors and clinics.

What is DISQVER?

Conventional diagnostic methods based on blood cultures usually require from two days to several weeks to identify a limited set of pathogens. Noscendo’s DISQVER platform identifies more than 16,000 microbes including 1,500 described pathogens (bacteria, DNA viruses, fungi and parasites) within 24 hours.

The cell-free DNA in the patient’s blood is determined using next-generation sequencing (NGS), a new, exceptionally fast method for DNA analysis. DISQVER’s bioinformatics algorithms compare this information against Noscendo clinical grade genome reference database. A report detailing all relevant pathogens detected in the sample is provided within a few hours. This knowledge can be used for blood stream infections and sepsis, in oncological diagnostics or diagnostics for endocarditis, for example.

Test DISQVER now!

Would you like to find out more or test DISQVER in your clinic?

ADVANTAGES OF DISQVER
AT A GLANCE

P

Cell-free DNA as new and more abundant biomarker allows precise analysis of the microbial load at the time of blood collection

P

Detects bacteria, fungi, DNA viruses and parasites from a standard blood sample using next-generation sequencing

P

Reliably identifies difficult and non-cultivatable pathogens

P

Independent of an already started anti-infective therapy

P

Without prior cultivation or prior knowledge of the possible cause of infection

P

Reliable statement on the exclusion of an infection

How DISQVER works

About noscendo

Noscendo is the leading global provider of software-based pathogen identification technology. We’ve made it our objective to revolutionise infection diagnostics, thus saving patient lives. To do so, we combine the latest molecular biology methods, such as next-generation sequencing (NGS), with proprietary bio IT solutions in our analysis platform DISQVER. Scores of well-known university hospitals, major regional hospitals and hospital groups are already using DISQVER. We also work with health insurance providers such as TK and IKK Südwest.

News

newsEN
Heiner Dreismann joins Noscendo’s Board of Directors

Noscendo GmbH, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections announced today the addition of Heiner Dreismann, former President and CEO of Roche Molecular Systems, to its Board of Directors

More precise diagnostics, more knowledge

Noscendo’s DISQVER platform compares cell-free DNA determined from the patient sample using next-generation sequencing with a clinical genome database. This makes it possible to identify harmful pathogens that cannot be verified using conventional methods.

Within 24 hours, DISQVER can identify:

microbes

pathogens

viruses

bacteria

fungi

parasites

    Contact us

    Information for physicians

    More precise diagnostics – more knowledge: Find out more about the clinical use of DISQVER!

    How DISQVER works

    Information for medical disciplines

    Publications

    News

    Read more about Noscendo and DISQVER or visit us at trade fairs and conferences!

    All News

    Publications

    Events

    Press

    Company

    DISQVER together – get to know Noscendo!

    Noscendo

    Team

    Advisory Board

    Career